Non-linear absorption pharmacokinetics of amoxicillin: Consequences for dosing regimens and clinical breakpoints

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 10, 2016, Pages 2909-2917

  de Velde, Femke ^a   de Winter, Brenda C M ^a   Koch, Birgit C P ^a   van Gelder, Teun ^a   Mouton, Johan W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CENTRAL VOLUME OF DISTRIBUTION; COMPARTMENT MODEL; CROSSOVER PROCEDURE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN TRANSIT TIME; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NORMAL HUMAN; OPEN STUDY; PERIPHERAL VOLUME OF DISTRIBUTION; PLASMA CONCENTRATION-TIME CURVE; TIME TO MAXIMUM PLASMA CONCENTRATION; ABSORPTION; ADOLESCENT; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; MIDDLE AGED; MONTE CARLO METHOD; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ABSORPTION, PHYSIOLOGICAL; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; YOUNG ADULT;

EID: 84994718447     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw226     Document Type: Article

References (32)

1. European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Consumption in Europe 2012. Stockholm: 2014. http://ecdc. europa.eu/en/publications/Publications/antimicrobial-consumptioneurope-esac-net-2012.pdf.
2. Mouton JW, Ambrose PG, Canton R et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14: 107-17.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10.
4. Mouton JW, Brown DF, Apfalter P et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012; 18: E37-45.
5. MacGowan AP. Elements of design: the knowledge on which we build. Clin Microbiol Infect 2004; 10 Suppl 2: 6-11.
6. European Committee on Antimicrobial Susceptibility Testing. Amoxicillin. Rationale for the EUCAST Clinical Breakpoints, Version 1.0, 2010. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_ documents/Amoxicillin_rationale_Nov2010_v_1.0.pdf.
7. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokineticspharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
8. Knudsen JD, Odenholt I, Erlendsdottir H et al. Selection of resistant Streptococcus pneumoniae during penicillin treatment in vitro and in three animal models. Antimicrob Agents Chemother 2003; 47: 2499-506.
9. Spyker DA, Rugloski RJ, Vann RL et al. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrob Agents Chemother 1977; 11: 132-41.
10. Zhang J, Wang Y, Xie H et al. Pharmacokinetics study of amoxycillin and clavulanic acid (8:1)-a newcombination in healthy Chinese adultmale volunteers using the LC-MS/MS method. Cell Biochem Biophys 2013; 65: 363-72.
11. Chulavatnatol S, Charles BG. Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects. Br J Clin Pharmacol 1994; 38: 274-7.
12. Sjövall J, Alvan G, Westerlund D. Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther 1985; 38: 241-50.
13. Piotrovskij VK, Paintaud G, Alvan G et al. Modeling of the saturable time-constrained amoxicillin absorption in humans. Pharm Res 1994; 11: 1346-51.
14. Bulitta J. Innovative techniques for selecting the dose of antibiotics in empiric therapy-focus on b-lactams and cystic fibrosis patients. Dissertation. Würzburg: Julius-Maximilians-Universität, 2006.
15. SmithKline Beecham. Comparison of the 24-hour pharmacokinetic profile of oral Augmentin administered with food to healthy male volunteers as 1 g 12 hourly versus 625 mg 8 hourly, and as 625 mg 12 hourly versus 375 mg 8 hourly (study 25000/360, final report). Harlow: 1994.
16. Zhang Y, Huo M, Zhou J et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010; 99: 306-14.
17. Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2013; 2: e50.
18. Savic RM, Jonker DM, Kerbusch T et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2007; 34: 711-26.
19. Boeckmann A, Sheiner L, Beal S. NONMEM Users Guide-Part V. Ellicott City, MD: ICON Development Solutions, 2011.
20. GlaxoSmithKline. Summary of Product Characteristics: Augmentin Amoxicillin/Clavulanic Acid 500 mg/125 mg Oral Tablets. Zeist: 2013.
21. Muller AE, Dorr PJ, Mouton JW et al. The influence of labour on the pharmacokinetics of intravenously administered amoxicillin in pregnant women. Br J Clin Pharmacol 2008; 66: 866-74.
22. Arancibia A, Guttmann J, Gonzalez G et al. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother 1980; 17: 199-202.
23. Dalhoff A, Koeppe P, von Kobyletzki D. Untersuchungen zur Pharmakokinetik von Amoxicillin nach intravenoser, intramuskularer und oraler Applikation. Arzneimittelforschung 1981; 31: 1148-57.
24. SmithKline Beecham. Comparison of the 24-hour Pharmacokinetic Profile of Oral Augmentin Administered to Healthy Male Volunteers as 1 g 12. hourly versus 625 mg 8 hourly, and as 625 mg 12 hourly versus 375. mg 8 hourly (Study 25000/256, Final Report). Harlow: 1994.
25. Welling PG, Huang H, Koch PA et al. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci 1977; 66: 549-52.
26. Tsuji A, Nakashima E, Hamano S et al. Physicochemical properties of amphoteric b-lactamantibiotics I: stability, solubility, and dissolution behavior of amino penicillins as a function of pH. J Pharm Sci 1978; 67: 1059-66.
27. Sjövall J. Dose dependence in human absorption of aminopenicillins. Infection 1979; 7 Suppl 5: S458-62.
28. Kimura T, Endo H, Yoshikawa M et al. Carrier-mediated transport systems for aminopenicillins in rat small intestine. J Pharm Dyn 1978; 1: 262-7.
29. Tsuji A, Nakashima E, Kagami I et al. Effect of dose-concentration on the absorption of amoxicillin and ampicillin from the rat intestine. J Pharm Pharmacol 1977; 29: 707-8.
30. Nord CE, Edlund C. Impact of antimicrobial agents on human intestinal microflora. J Chemother 1990; 2: 218-37.
31. Crokaert F, van der LindenMP, Yourassowsky E. Activities of amoxicillin and clavulanic acid combinations against urinary tract infections. Antimicrob Agents Chemother 1982; 22: 346-9.
32. Adam D, de Visser I, Koeppe P. Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother 1982; 22: 353-7.